NetworkNewsBreaks – Pivot Pharmaceuticals Inc. (
Post# of 52
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has accelerated development of several cannabidiol (“CBD”) products for the domestic pet food market. Pivot’s pet product line will be marketed under the brand “Pivot Naturals For Pets” and will include capsules and sachets that deliver bio-available CBD to pets produced using the company’s patented Ready-To-Infuse-Cannabis powder as well as a line of pet creams developed using its Thrudermic Transdermal Nanotechnology. Pivot Naturals For Pets products will target indications such as joint pain, inflammation, post-surgical pain and skin disorders. “Pivot’s technologies are versatile and allow us to develop and commercialize products for both the human and veterinary markets. Our suite of patented technologies will allow us to continually innovate and bring dozens of differentiated, value-added derivatives to market, where regulations permit, in Canada, U.S. and the EU,” Dr. Joseph Borovksy, Pivot Executive VP, Product Development stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer